A NARCOMS survey reveals that most people with multiple sclerosis who qualify for GLP-1 medications are not currently using them. The finding highlights a significant gap between eligibility and actual treatment among MS patients.
A recent survey conducted by NARCOMS has found that the majority of individuals with multiple sclerosis who meet the criteria for GLP-1 drugs are not taking these medications. The survey results indicate a substantial disconnect between eligibility and actual use among MS patients.
According to the NARCOMS survey, most people with MS who qualify for GLP-1 therapies are not receiving them. This finding was reported by the survey, which examined medication usage patterns in the MS community. The data show a low rate of GLP-1 drug uptake among eligible patients.
The NARCOMS survey specifically assessed GLP-1 drug use in multiple sclerosis patients who meet the requirements for these medications. The survey's primary result is that the majority of eligible MS patients are not using GLP-1 drugs. This information comes directly from the NARCOMS survey.
The survey was carried out by NARCOMS, an organization that conducts research on multiple sclerosis. The exact methodology and sample size of the survey are not detailed in the available information. However, the key finding is clear: most people with MS who are eligible for GLP-1 drugs are not taking them.
Based on the NARCOMS survey, many MS patients who could potentially benefit from GLP-1 medications are not currently using them. The survey highlights a gap between the number of eligible patients and those actually receiving GLP-1 therapy. This result was obtained from the NARCOMS survey.
The NARCOMS survey reports that most MS patients who qualify for GLP-1 drugs are not taking these medications. This finding suggests a significant underutilization of GLP-1 therapies in the MS population. The survey provides evidence that many eligible patients are missing out on GLP-1 treatment.
The NARCOMS survey finding points to a treatment gap in MS care regarding GLP-1 drugs. Most patients with MS who are eligible for these medications are not receiving them, according to the survey. This result may prompt further investigation into why eligible patients are not using GLP-1 drugs.
The survey from NARCOMS indicates that the majority of MS patients who qualify for GLP-1 drugs are not taking them. This finding is based on the survey data. The NARCOMS survey provides this important information about GLP-1 drug use in MS.
In summary, the NARCOMS survey found that most people with multiple sclerosis who are eligible for GLP-1 drugs are not currently taking them. The survey results highlight a mismatch between eligibility and actual medication use. This finding comes from the NARCOMS survey.
Peptides referenced: GLP-1.
Related reading: GLP-1 Injection Customers Lost Thousands; Wellness Founder Charged with 10 Felonies, Employers steer workers to HSAs, counseling to avoid GLP-1 weight loss coverage, Crocin II Targets ANGPTL8 to Reduce MASLD Progression in Preclinical Study, GLP-1 Drug Costs Push Dallas Health Plan Over Budget.